WASHINGTON - The Food and Drug Administration has launched what it is describing as a "unified dashboard" for identifying and ...
Pooled data from PsA and axSpA extension studies provide early reassurance ...
ASH 2025 data emphasize that standardized protocols and strong academic-community communication are essential for safe and consistent management of bispecific antibody adverse events in community ...
The evaluation of drug safety in clinical trials is a critical element of the drug development process, ensuring that therapeutic benefits outweigh potential harms. Clinical trials, particularly in ...
As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and reshape the U.S' healthcare infrastructure, the U.S. drug regulator has unveiled ...
The addition of pembrolizumab to chemotherapy in high-risk early triple-negative breast cancer (TNBC) improves cancer outcomes. However, pembrolizumab induces varied immune-related adverse events ...
Zanubrutinib shows sustained superior PFS in CLL patients without del(17p), regardless of IGHV mutation status. The safety profile of zanubrutinib remains consistent, with low atrial fibrillation ...
Health care workers face adverse events daily. These events include secondary trauma, occupational trauma, unexpected death or injury, moral injury, medical error and ...